• Product name

    Anti-CD24 antibody [EPR3006(N)]
    See all CD24 primary antibodies
  • Description

    Rabbit monoclonal [EPR3006(N)] to CD24
  • Host species

  • Tested applications

    Suitable for: WB, IPmore details
    Unsuitable for: Flow Cyt,ICC/IF or IHC-P
  • Species reactivity

    Reacts with: Human
    Does not react with: Mouse, Rat
  • Immunogen

    This information is considered to be commercially sensitive.

  • Positive control

    • Human fetal brain, SH-SY5Y cell and human oligodendroglioma lysates.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.


Our Abpromise guarantee covers the use of ab179821 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 8 kDa.
IP 1/10 - 1/100.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF or IHC-P.
  • Target

    • Function

      Modulates B-cell activation responses. Signaling could be triggered by the binding of a lectin-like ligand to the CD24 carbohydrates, and transduced by the release of second messengers derived from the GPI-anchor. Promotes AG-dependent proliferation of B-cells, and prevents their terminal differentiation into antibody-forming cells.
    • Tissue specificity

      B-cells. Expressed in a number of B-cell lines including P32/SH and Namalwa. Expressed in erythroleukemia cell and small cell lung carcinoma cell lines. Also expressed on the surface of T-cells.
    • Involvement in disease

      Genetic variations in CD24 are associated with susceptibility to multiple sclerosis (MS) [MIM:126200]. A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheat, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. Note=Polymorphisms in CD24 may act as a genetic modifier for susceptibility and progression of MS in some populations, perhaps by affecting the efficiency of CD24 expression on the cell surface.
    • Sequence similarities

      Belongs to the CD24 family.
    • Post-translational

      Extensively O-glycosylated.
    • Cellular localization

      Cell membrane.
    • Information by UniProt
    • Database links

    • Alternative names

      • CD 24 antibody
      • CD24 antibody
      • CD24 antigen (small cell lung carcinoma cluster 4 antigen) antibody
      • CD24 antigen antibody
      • CD24 molecule antibody
      • CD24_HUMAN antibody
      • CD24A antibody
      • FLJ22950 antibody
      • FLJ43543 antibody
      • GPI linked surface mucin antibody
      • Heat stable antigen antibody
      • HSA antibody
      • MGC75043 antibody
      • Nectadrin antibody
      • Signal transducer CD24 antibody
      • Small cell lung carcinoma cluster 4 antigen antibody
      see all


    • All lanes : Anti-CD24 antibody [EPR3006(N)] (ab179821) at 1/1000 dilution

      Lane 1 : fetal brain lysate
      Lane 2 : SH-SY5Y cell lysate
      Lane 3 : human oligodendroglioma lysate

      Lysates/proteins at 10 µg per lane.

      Predicted band size: 8 kDa

    • Western blot analysis on immunoprecipitation pellet from (1) SH-SY5Y cell lysate or (2) 1X PBS (negative control) labeling CD24 using ab179821 at 1/10 dilution, and HRP-conjugated anti-rabbit IgG preferentially detecting the non-reduced form of rabbit IgG.


    This product has been referenced in:

    • Zhang J  et al. LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/ß-catenin pathway and predicts poor survival of glioma patients. J Exp Clin Cancer Res 37:225 (2018). Read more (PubMed: 30208924) »
    See 1 Publication for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab179821.
    Please use the links above to contact us or submit feedback about this product.

    For licensing inquiries, please contact partnerships@abcam.com

    Sign up